Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
[fabry disease]
Fabry
disease
is
an
X-
linked
inherited
lysosomal
storage
disease
that
can
be
treated
with
the
enzymes
of
agalsidase
beta
(
Fabrazyme
)
and
agalsidase
alfa
(
Replagal
)
.
Since
June
2009
,
viral
contamination
of
Genzyme
's
production
facility
has
resulted
in
a
worldwide
shortage
of
agalsidase
beta
,
leading
to
the
switch
to
agalsidase
alfa
for
patients
with
Fabry
disease
in
Taiwan
.
T
he
medical
records
were
retrospectively
reviewed
for
nine
male
patients
with
Fabry
disease
from
the
start
of
agalsidase
beta
treatment
until
the
switch
to
agalsidase
alfa
for
at
least
1
year
.
After
12
-
112
months
of
enzyme
replacement
therapy
(
ERT
)
,
decreased
plasma
globotriaosylsphingosine
(
lyso-
Gb
3
)
was
found
in
five
out
of
seven
patients
,
indicating
improvement
in
disease
severity
.
Among
the
six
patients
with
available
echocardiographic
data
at
baseline
and
after
ERT
,
all
six
experienced
reductions
of
left
ventricular
mass
index
.
Renal
function
,
including
microalbuminuria
and
estimated
glomerular
filtration
rate
,
showed
stability
after
ERT
.
Mainz
Severity
Score
Index
scores
revealed
that
all
nine
patients
remained
stable
at
12
months
after
switching
to
agalsidase
alfa
.
ERT
improved
or
stabilized
cardiac
status
and
stabilized
renal
function
,
while
reducing
plasma
lyso-
Gb
3
.
ERT
was
well
tolerated
,
even
among
the
three
patients
who
had
hypersensitivity
reactions
.
The
switch
of
ERT
from
agalsidase
beta
to
agalsidase
alfa
appears
to
be
safe
after
1
year
of
follow-up
for
Taiwanese
patients
with
Fabry
disease
.
Diseases
Validation
Diseases presenting
"the switch to agalsidase alfa for patients with fabry disease in taiwan"
symptom
fabry disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom